Rib-X Pharmaceuticals, Inc.
Rib-X Pharmaceuticals, Inc. designs and develops novel small-molecule antibiotics for the treatment of serious infections. Its products include delafloxacin, which is used for complicated skin and soft tissue infections; and radezolid, which is used for community acquired pneumonia, and uncomplicated skin and soft tissue infections. The company’ products are also used for the treatment of serious hospital gram-negative infections. Rib-X Pharmaceuticals, Inc. was founded in 2000 and is based in New Haven, Connecticut.
Contact Details
Executives
Chairman
George M. Milne Jr.
President, CEO, and Director
Susan Froshauer